L2G Score in the New Platform: Causality or druggability

Community Feedback Data issue
1

Hello Open Targets team,

I’m working on gene causality analysis and have been using the Open Targets Genetics platform, specifically the L2G (locus-to-gene) score, as a measure of gene causality. In the new release on the new platform, I noticed that terminology has shifted to focus on “Targets” instead of “Genes.” I wanted to clarify whether the L2G score in the new release still represents gene causality only, or if it now also incorporates druggability or therapeutic potential.

I rely on the L2G score to identify causal genes, using a cutoff of 0.5 for my analyses, and I want to ensure that the score still has the same interpretation. Could you please confirm whether the L2G score remains a pure causality measure or if it now combines druggability as well?

Thank you for your support!

2

Hi @BushraDohai,

The L2G score predicts the likelihood a gene is causal for a particular GWAS locus. The machine learning model uses 28 features divided into four categories: distance, colocalisation, variant effect, and other (gene count, protein gene count, and credible set confidence).

You can find out more in the documentation: Locus-to-Gene (L2G) | Open Targets Platform Documentation

The score still has the same interpretation, and does not incorporate druggability or therapeutic potential.

Let us know if you have further questions!

Helena

3

Thanks Helena for your quick reply :slight_smile: